Controlled Substances: Proposed Revised Aggregate Production Quotas for 2009, 36511-36515 [E9-17536]

Download as PDF Federal Register / Vol. 74, No. 140 / Thursday, July 23, 2009 / Notices erowe on DSK5CLS3C1PROD with NOTICES (4) Affected public who will be asked or required to respond, as well as a brief abstract: State agencies, tribal governments, local governments, colleges and universities, non-profit organizations, and for-profit organizations. The purpose of the Recovery Act solicitation template is to provide a framework to develop program-specific announcements soliciting applications for funding. A program solicitation outlines the specifics of the funding program; describes requirements for eligibility; instructs an applicant on the necessary components of an application under a specific program (e.g., project activities and timeline, proposed budget); and provides registration dates, due dates, and instructions on how to apply within the designated application system. (5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond/reply: It is estimated that information will be collected annually from 250 applicants, representing State agencies, tribal governments, local governments, colleges and universities, non-profit organizations, and for-profit organizations. Annual cost to the respondents is based on the number of hours involved in preparing and submitting a complete application package. Public reporting burden for this collection of information is estimated at up to 30 hours per application. The 30-hour estimate is based on the amount of time to prepare research and evaluation proposals, one of the most time intensive types of applications solicited by OJP. The estimate of burden hours is based on OJP’s prior experience with the application submission process. (6) An estimate of the total public burden (in hours) associated with the collection: The estimated public burden associated with this collection is 7,500 hours. If additional information is required contact: Mrs. Lynn Bryant, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Suite 1600, 601 D Street, NW., Washington, DC 20530. Dated: July 20, 2009. Lynn Bryant, Department Clearance Officer, PRA, United States Department of Justice. [FR Doc. E9–17569 Filed 7–22–09; 8:45 am] BILLING CODE 4410–18–P VerDate Nov<24>2008 15:01 Jul 22, 2009 Jkt 217001 DEPARTMENT OF JUSTICE Office of Justice Programs Office of Juvenile Justice and Delinquency Prevention [OMB Number 1121–0218] Agency Information Collection Activities: Proposed Collection; Comments Requested ACTION: 60-Day Notice of Information Collection Under Review; Census of Juveniles in Residential Placement (Reinstatement, without change, of a previously approved collection for which approval has expired). The Department of Justice (DOJ), Office of Justice Programs, Office of Juvenile Justice and Delinquency Prevention, will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted for ‘‘sixty days’’ until September 21, 2009. This process is conducted in accordance with 5 CFR 1320.10. If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Janet Chiancone, (202) 353–9258, Office of Juvenile Justice and Delinquency Prevention, Office of Justice Programs, U.S. Department of Justice, 810 Seventh Street, NW., Washington, DC 20531. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Enhance the quality, utility, and clarity of the information to be collected; and —Minimize the burden of the collection of information on those who are to PO 00000 Frm 00064 Fmt 4703 Sfmt 4703 36511 respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. Overview of this information collection: (1) Type of information collection: Extension of previously approved collection. (2) The title of the form/collection: Census of Juveniles in Residential Placement. (3) The agency form number, if any, and the applicable component of the Department sponsoring the collection: The form number is CJ–14, Office of Juvenile Justice and Delinquency Prevention, United States Department of Justice. (4) Affected public who will be asked or required to respond, as well as a brief abstract: Primary: Federal Government, State, Local or Tribal. Other: Not-forprofit institutions; business or other forprofit. (5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond/reply: It is estimated that 3,500 respondents will complete a 3-hour questionnaire. (6) An estimate of the total public burden (in hours) associated with the collection: Approximately 11,550 hours. If additional information is required contact: Lynn Bryant, Department Clearance Officer, U.S. Department of Justice, Justice Management Division, Policy and Planning Staff, Patrick Henry Building, Suite 1600, 601 D Street NW., Washington, DC 20530. Dated: July 20, 2009. Lynn Bryant, Department Deputy Clearance Officer, PRA, U.S. Department of Justice. [FR Doc. E9–17565 Filed 7–22–09; 8:45 am] BILLING CODE 4410–18–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–317R] Controlled Substances: Proposed Revised Aggregate Production Quotas for 2009 AGENCY: Drug Enforcement Administration (DEA), Justice. ACTION: Notice of proposed revised 2009 aggregate production quotas. SUMMARY: This notice proposes revised 2009 aggregate production quotas for E:\FR\FM\23JYN1.SGM 23JYN1 36512 Federal Register / Vol. 74, No. 140 / Thursday, July 23, 2009 / Notices controlled substances in schedules I and II of the Controlled Substances Act (CSA). DATES: Written comments must be postmarked, and electronic comments must be sent, on or before August 24, 2009. ADDRESSES: To ensure proper handling of comments, please reference ‘‘Docket No. DEA–317R’’ on all written and electronic correspondence. Written comments should be sent to the DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 8701 Morrissette Drive, Springfield, VA 22152. Comments may be directly sent to DEA electronically by sending an electronic message to dea.diversion.policy@usdoj.gov. An electronic copy of this document is also available at the https:// www.regulations.gov Web site. However, persons wishing to request a hearing should note that such requests must be written and manually signed; requests for a hearing will not be accepted via electronic means. DEA will accept attachments to electronic comments in Microsoft Word, WordPerfect, Adobe PDF, or Excel file formats only. DEA will not accept any file format other than those specifically listed here. FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, Ph.D., Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, 8701 Morrissette Drive, Springfield, VA 22152, or by telephone at (202) 307– 7183. Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in schedules I and II. This responsibility has been delegated to the Administrator of the DEA by 28 CFR 0.100. The Administrator in turn, has redelegated this function to the Deputy Administrator, pursuant to 28 CFR 0.104. On November 7, 2008, a notice of proposed 2009 aggregate production quotas for certain controlled substances in schedules I and II was published in the Federal Register (73 FR 66256). This notice stipulated that the DEA would adjust the quotas in 2009 as provided for in 21 CFR part 1303. The proposed revised 2009 aggregate production quotas represent those SUPPLEMENTARY INFORMATION: quantities of controlled substances in schedules I and II that may be produced in the United States in 2009 to provide adequate supplies of each substance for: The estimated medical, scientific, research and industrial needs of the United States; lawful export requirements; and the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes. The proposed revisions are based on a review of 2008 year-end inventories, 2008 disposition data submitted by quota applicants, estimates of the medical needs of the United States, product development, and other information available to the DEA. Therefore, under the authority vested in the Attorney General by Section 306 of the CSA (21 U.S.C. 826), and delegated to the Administrator of the DEA by 28 CFR 0.100, and redelegated to the Deputy Administrator pursuant to 28 CFR 0.104, the Deputy Administrator hereby proposes the following revised 2009 aggregate production quotas for the following controlled substances, expressed in grams of anhydrous acid or base: Previously established initial 2009 quotas erowe on DSK5CLS3C1PROD with NOTICES Basic class—schedule I 2,5-Dimethoxyamphetamine .................................................................................................................... 2,5-Dimethoxy-4-ethylamphetamine (DOET) .......................................................................................... 3-Methylfentanyl ....................................................................................................................................... 3-Methylthiofentanyl ................................................................................................................................. 3,4-Methylenedioxyamphetamine (MDA) ................................................................................................ 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ................................................................................. 3,4-Methylenedioxymethamphetamine (MDMA) ..................................................................................... 3,4,5-Trimethoxyamphetamine ................................................................................................................ 4-Bromo-2,5-dimethoxyamphetamine (DOB) .......................................................................................... 4-Bromo-2,5-dimethoxyphenethylamine (2–CB) ..................................................................................... 4-Methoxyamphetamine .......................................................................................................................... 4-Methylaminorex .................................................................................................................................... 4-Methyl-2,5-dimethoxyamphetamine (DOM) .......................................................................................... 5-Methoxy-3,4-methylenedioxyamphetamine .......................................................................................... 5-Methoxy-N,N-diisopropyltryptamine ...................................................................................................... Acetyl-alpha-methylfentanyl ..................................................................................................................... Acetyldihydrocodeine ............................................................................................................................... Acetylmethadol ........................................................................................................................................ Allylprodine .............................................................................................................................................. Alphacetylmethadol .................................................................................................................................. Alpha-ethyltryptamine .............................................................................................................................. Alphameprodine ....................................................................................................................................... Alphamethadol ......................................................................................................................................... Alpha-methylfentanyl ............................................................................................................................... Alpha-methylthiofentanyl .......................................................................................................................... Aminorex .................................................................................................................................................. Benzylmorphine ....................................................................................................................................... Betacetylmethadol ................................................................................................................................... Beta-hydroxy-3-methylfentanyl ................................................................................................................ Beta-hydroxyfentanyl ............................................................................................................................... Betameprodine ......................................................................................................................................... Betamethadol ........................................................................................................................................... Betaprodine .............................................................................................................................................. Bufotenine ................................................................................................................................................ Cathinone ................................................................................................................................................. Codeine-N-oxide ...................................................................................................................................... VerDate Nov<24>2008 15:01 Jul 22, 2009 Jkt 217001 PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 E:\FR\FM\23JYN1.SGM 2 2 2 2 25 10 20 2 2 2 27 2 2 2 5 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 3 602 23JYN1 Proposed revised 2009 quotas g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g 2 2 2 2 25 10 20 2 2 2 27 2 2 2 5 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 3 3 602 g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g 36513 Federal Register / Vol. 74, No. 140 / Thursday, July 23, 2009 / Notices Previously established initial 2009 quotas Basic class—schedule I Diethyltryptamine ..................................................................................................................................... Difenoxin .................................................................................................................................................. Dihydromorphine ...................................................................................................................................... Dimethyltryptamine .................................................................................................................................. Gamma-hydroxybutyric acid .................................................................................................................... Heroin ...................................................................................................................................................... Hydromorphinol ........................................................................................................................................ Hydroxypethidine ..................................................................................................................................... Ibogaine ................................................................................................................................................... Lysergic acid diethylamide (LSD) ............................................................................................................ Marihuana ................................................................................................................................................ Mescaline ................................................................................................................................................. Methaqualone .......................................................................................................................................... Methcathinone ......................................................................................................................................... Methyldihydromorphine ............................................................................................................................ Morphine-N-oxide .................................................................................................................................... N-Benzylpiperazine .................................................................................................................................. N,N-Dimethylamphetamine ...................................................................................................................... N-Ethylamphetamine ............................................................................................................................... N-Hydroxy-3,4-methylenedioxyamphetamine .......................................................................................... Noracymethadol ....................................................................................................................................... Norlevorphanol ......................................................................................................................................... Normethadone ......................................................................................................................................... Normorphine ............................................................................................................................................ Para-fluorofentanyl ................................................................................................................................... Phenomorphan ........................................................................................................................................ Pholcodine ............................................................................................................................................... Psilocybin ................................................................................................................................................. Psilocyn .................................................................................................................................................... Tetrahydrocannabinols ............................................................................................................................ Thiofentanyl ............................................................................................................................................. Trimeperidine ........................................................................................................................................... erowe on DSK5CLS3C1PROD with NOTICES 1-Phenylcyclohexylamine ........................................................................................................................ 1-Piperdinocyclohexanecarbonitrile ......................................................................................................... Alfentanil .................................................................................................................................................. Alphaprodine ............................................................................................................................................ Amobarbital .............................................................................................................................................. Amphetamine (for sale) ........................................................................................................................... Amphetamine (for conversion) ................................................................................................................ Cocaine .................................................................................................................................................... Codeine (for sale) .................................................................................................................................... Codeine (for conversion) ......................................................................................................................... Dextropropoxyphene ................................................................................................................................ Dihydrocodeine ........................................................................................................................................ Diphenoxylate .......................................................................................................................................... Ecgonine .................................................................................................................................................. Ethylmorphine .......................................................................................................................................... Fentanyl ................................................................................................................................................... Glutethimide ............................................................................................................................................. Hydrocodone (for sale) ............................................................................................................................ Hydromorphone ....................................................................................................................................... Isomethadone .......................................................................................................................................... Levo-alphacetylmethadol (LAAM) ............................................................................................................ Levomethorphan ...................................................................................................................................... Levorphanol ............................................................................................................................................. Lisdexamfetamine .................................................................................................................................... Meperidine ............................................................................................................................................... Meperidine Intermediate-A ...................................................................................................................... Meperidine Intermediate-B ...................................................................................................................... Meperidine Intermediate-C ...................................................................................................................... Metazocine ............................................................................................................................................... Methadone (for sale) ............................................................................................................................... Methadone Intermediate .......................................................................................................................... Methamphetamine ................................................................................................................................... 15:01 Jul 22, 2009 Jkt 217001 PO 00000 Frm 00066 g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g Previously established initial 2009 quotas Basic class—schedule II VerDate Nov<24>2008 2 3,000 2,549,000 3 24,200,00 20 2 2 1 10 4,500,000 7 5 4 2 605 2 7 2 2 2 52 2 16 2 2 2 7 7 312,500 2 2 Proposed revised 2009 quotas Fmt 4703 Sfmt 4703 E:\FR\FM\23JYN1.SGM 2 2 8,000 2 3 17,000,000 5,000,000 247,000 39,605,000 65,000,000 106,000,000 1,200,000 947,000 83,000 2 1,428,000 2 55,000,000 3,300,000 2 3 5 10,000 6,200,000 8,600,000 3 7 3 1 25,000,000 26,000,000 3,130,000 23JYN1 2 3,000 2,549,000 3 24,200,000 20 2 2 1 10 4,500,000 7 5 4 2 605 2 7 2 2 2 52 2 16 2 2 2 7 7 312,500 2 2 g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g Proposed revised 2009 quotas g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g 2 2 8,000 2 3 17,000,000 5,000,000 247,000 39,605,000 65,000,000 106,000,000 1,200,000 947,000 83,000 2 1,428,000 2 55,000,000 3,300,000 2 3 5 10,000 6,200,000 8,600,000 3 7 3 1 25,000,000 26,000,000 3,130,000 g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g g 36514 Federal Register / Vol. 74, No. 140 / Thursday, July 23, 2009 / Notices Previously established initial 2009 quotas Basic class—schedule II Proposed revised 2009 quotas [680,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,405,000 grams for methamphetamine mostly for conversion to a schedule III product; and 45,000 grams for methamphetamine (for sale)] Methylphenidate ....................................................................................................................................... Morphine (for sale) .................................................................................................................................. Morphine (for conversion) ........................................................................................................................ Nabilone ................................................................................................................................................... Noroxymorphone (for sale) ...................................................................................................................... Noroxymorphone (for conversion) ........................................................................................................... Opium (powder) ....................................................................................................................................... Opium (tincture) ....................................................................................................................................... Oripavine .................................................................................................................................................. Oxycodone (for sale) ............................................................................................................................... Oxycodone (for conversion) .................................................................................................................... Oxymorphone .......................................................................................................................................... Oxymorphone (for conversion) ................................................................................................................ Pentobarbital ............................................................................................................................................ Phenazocine ............................................................................................................................................ Phencyclidine ........................................................................................................................................... Phenmetrazine ......................................................................................................................................... Phenylacetone ......................................................................................................................................... Racemethorphan ..................................................................................................................................... Remifentanil ............................................................................................................................................. Secobarbital ............................................................................................................................................. Sufentanil ................................................................................................................................................. Tapentadol 1 ............................................................................................................................................. Thebaine .................................................................................................................................................. 50,000,000 35,000,000 100,000,000 9,002 10,000 9,000,000 1,050,000 230,000 15,000,000 77,560,000 3,400,000 2,000,000 12,000,000 28,000,000 1 20 2 1 2 500 67,000 10,300 0 126,000,000 g g g g g g g g g g g g g g g g g g g g g g g g 50,000,000 35,000,000 100,000,000 9,002 10,000 9,000,000 230,000 1,050,000 15,000,000 77,560,000 3,400,000 2,000,000 12,000,000 28,000,000 1 20 2 1 2 500 67,000 10,300 519,000 126,000,000 g g g g g g g g g g g g g g g g g g g g g g g g erowe on DSK5CLS3C1PROD with NOTICES 1 Tapentadol was placed in schedule II of the Controlled Substances Act by a final order published by the Drug Enforcement Administration on May 21, 2009 (74 FR 23790). The Deputy Administrator further proposes that aggregate production quotas for all other schedules I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. All interested persons are invited to submit their comments in writing or electronically regarding this proposal following the procedures in the ADDRESSES section of this document. A person may object to or comment on the proposal relating to any of the abovementioned substances without filing comments or objections regarding the others. If a person believes that one or more of these issues warrant a hearing, the individual should so state and summarize the reasons for this belief. Persons wishing to request a hearing should note that such requests must be written and manually signed; requests for a hearing will not be accepted via electronic means. In the event that comments or objections to this proposal raise one or more issues which the Deputy Administrator finds warrant a hearing, the Deputy Administrator shall order a public hearing by notice in the Federal Register, summarizing the issues to be heard and setting the time for the hearing as per 21 CFR 1303.13(c). VerDate Nov<24>2008 15:01 Jul 22, 2009 Jkt 217001 Regulatory Certifications Regulatory Flexibility Act The Deputy Administrator hereby certifies that this action will not have a significant economic impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601–612. The establishment of aggregate production quotas for schedules I and II controlled substances is mandated by law and by international treaty obligations. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for lawful export requirements, and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Deputy Administrator has determined that this action does not require a regulatory flexibility analysis. Executive Order 12866 The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. Executive Order 13132 This action does not preempt or modify any provision of state law; nor PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 does it impose enforcement responsibilities on any state; nor does it diminish the power of any state to enforce its own laws. Accordingly, this action does not have federalism implications warranting the application of Executive Order 13132. Executive Order 12988 This action meets the applicable standards set forth in Sections 3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform. Unfunded Mandates Reform Act of 1995 This action will not result in the expenditure by state, local, and tribal governments, in the aggregate, or by the private sector, of $120,000,000 or more (adjusted for inflation) in any one year, and will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the provisions of the Unfunded Mandates Reform Act of 1995. Congressional Review Act This action is not a major rule as defined by Section 804 of the Small Business Regulatory Enforcement Fairness Act of 1996 (Congressional Review Act). This action will not result in an annual effect on the economy of $100,000,000 or more; a major increase in costs or prices; or significant adverse effects on competition, employment, E:\FR\FM\23JYN1.SGM 23JYN1 Federal Register / Vol. 74, No. 140 / Thursday, July 23, 2009 / Notices investment, productivity, innovation, or on the ability of United States-based companies to compete with foreignbased companies in domestic and export markets. the prohibited transaction restrictions of the Employee Retirement Income Security Act of 1974 (ERISA or the Act) and/or the Internal Revenue Code of 1986 (the Code). Dated: July 16, 2009. Michele M. Leonhart, Deputy Administrator. [FR Doc. E9–17536 Filed 7–22–09; 8:45 am] Written Comments and Hearing Requests BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Foreign Claims Settlement Commission F.C.S.C. Meeting Notice No. 4–09 The Foreign Claims Settlement Commission, pursuant to its regulations (45 CFR Part 504) and the Government in the Sunshine Act (5 U.S.C. 552b), hereby gives notice in regard to the scheduling of meetings for the transaction of Commission business and other matters specified, as follows: Date and Time: Tuesday, July 28, 2009, at 11 a.m. Subject Matter: Issuance of Proposed Decisions in claims against Albania and Libya. Status: Open. All meetings are held at the Foreign claims Settlement Commission, 600 E Street, NW., Washington, DC. Requests for information, or advance notices of intention to observe an open meeting, may be directed to: Administrative Officer, Foreign Claims Settlement Commission, 600 E Street, NW., Room 6002, Washington, DC 20579. Telephone: (202) 616–6975. Dated at Washington, DC. Mauricio J. Tamargo, Chairman. [FR Doc. E9–17443 Filed 7–22–09; 8:45 am] BILLING CODE 4410–01–P DEPARTMENT OF LABOR Notice to Interested Persons Employee Benefits Security Administration [Application No. and Proposed Exemption Involving: Bank of New York Mellon Corporation, D–11553] erowe on DSK5CLS3C1PROD with NOTICES Notice of Proposed Exemption AGENCY: Employee Benefits Security Administration, Labor. ACTION: Notice of proposed exemption. SUMMARY: This document contains a notice of pendency before the Department of Labor (the Department) of a proposed exemption from certain of VerDate Nov<24>2008 15:01 Jul 22, 2009 Jkt 217001 All interested persons are invited to submit written comments or requests for a hearing on the pending exemption, unless otherwise stated in the Notice of Proposed Exemption, within 45 days from the date of publication of this Federal Register Notice. Comments and requests for a hearing should state: (1) The name, address, and telephone number of the person making the comment or request, and (2) the nature of the person’s interest in the exemption and the manner in which the person would be adversely affected by the exemption. A request for a hearing must also state the issues to be addressed and include a general description of the evidence to be presented at the hearing. ADDRESSES: All written comments and requests for a hearing (at least three copies) should be sent to the Employee Benefits Security Administration (EBSA), Office of Exemption Determinations, Room N–5649, U.S. Department of Labor, 200 Constitution Avenue, NW., Washington, DC 20210. Attention: Application No. D–11553. Interested persons are also invited to submit comments and/or hearing requests to EBSA via e-mail or FAX. Any such comments or requests should be sent either by e-mail to: moffitt.betty@dol.gov, or by FAX to (202) 219–0204 by the end of the scheduled comment period. The application for exemption and the comments received will be available for public inspection in the Public Documents Room of the Employee Benefits Security Administration, U.S. Department of Labor, Room N–1513, 200 Constitution Avenue, NW., Washington, DC 20210. Notice of the proposed exemption will be provided to all interested persons in the manner agreed upon by the applicant and the Department within 15 days of the date of publication in the Federal Register. Such notice shall include a copy of the notice of proposed exemption as published in the Federal Register and shall inform interested persons of their right to comment and to request a hearing (where appropriate). SUPPLEMENTARY INFORMATION: The proposed exemption was requested in an application filed pursuant to section PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 36515 408(a) of the Act and/or section 4975(c)(2) of the Code, and in accordance with procedures set forth in 29 CFR Part 2570, Subpart B (55 FR 32836, 32847, August 10, 1990). Effective December 31, 1978, section 102 of Reorganization Plan No. 4 of 1978, 5 U.S.C. App. 1 (1996), transferred the authority of the Secretary of the Treasury to issue exemptions of the type requested to the Secretary of Labor. Therefore, this notice of proposed exemption is issued solely by the Department. The application contains representations with regard to the proposed exemption which is summarized below. Interested persons are referred to the application on file with the Department for a complete statement of the facts and representations. Bank of New York Mellon Corporation Located in Pittsburgh, PA [Application No. D–11553] Proposed Exemption The Department is considering granting an exemption under the authority of section 408(a) of the Act and section 4975(c)(2) of the Code and in accordance with the procedures set forth in 29 CFR part 2570, subpart B (55 FR 32836, 32847, August 10, 1990). If the proposed exemption is granted, the restrictions of sections 406(a)(1)(A) through (D), 406(b)(1) and 406(b)(2) of the Act and the sanctions resulting from the application of section 4975 of the Code, by reason of section 4975(c)(1)(A) through (E) of the Code,1 shall not apply, effective November 25, 2008, to the cash sale of certain securities (the Securities) issued by Lehman Brothers Holdings Inc. or its affiliates (Lehman) for an aggregate purchase price of approximately $5,512,395 by the EB SMAM Securities Lending Temporary Investment Fund (the Cash Collateral Fund) to the Bank of New York Mellon Corporation (BNYMC), a party in interest with respect to the employee benefit plans (the Plan(s)) invested, directly or indirectly, in the Cash Collateral Fund; provided that the following conditions are met: (a) The sale of the Securities was a one-time transaction for cash; (b) The Cash Collateral Fund received an amount for the sale of the Securities which was equal to the sum of: (1) the amortized cost of the Securities, and (2) the accrued but 1 For purposes of this proposed exemption, references to specific provisions of Title I of the Act, unless otherwise specified, refer also to the corresponding provisions of the Code. E:\FR\FM\23JYN1.SGM 23JYN1

Agencies

[Federal Register Volume 74, Number 140 (Thursday, July 23, 2009)]
[Notices]
[Pages 36511-36515]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-17536]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-317R]


Controlled Substances: Proposed Revised Aggregate Production 
Quotas for 2009

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of proposed revised 2009 aggregate production quotas.

-----------------------------------------------------------------------

SUMMARY: This notice proposes revised 2009 aggregate production quotas 
for

[[Page 36512]]

controlled substances in schedules I and II of the Controlled 
Substances Act (CSA).

DATES: Written comments must be postmarked, and electronic comments 
must be sent, on or before August 24, 2009.

ADDRESSES: To ensure proper handling of comments, please reference 
``Docket No. DEA-317R'' on all written and electronic correspondence. 
Written comments should be sent to the DEA Headquarters, Attention: DEA 
Federal Register Representative/ODL, 8701 Morrissette Drive, 
Springfield, VA 22152. Comments may be directly sent to DEA 
electronically by sending an electronic message to 
dea.diversion.policy@usdoj.gov. An electronic copy of this document is 
also available at the https://www.regulations.gov Web site. However, 
persons wishing to request a hearing should note that such requests 
must be written and manually signed; requests for a hearing will not be 
accepted via electronic means. DEA will accept attachments to 
electronic comments in Microsoft Word, WordPerfect, Adobe PDF, or Excel 
file formats only. DEA will not accept any file format other than those 
specifically listed here.

FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, Ph.D., Chief, 
Drug and Chemical Evaluation Section, Drug Enforcement Administration, 
8701 Morrissette Drive, Springfield, VA 22152, or by telephone at (202) 
307-7183.

SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826) 
requires that the Attorney General establish aggregate production 
quotas for each basic class of controlled substance listed in schedules 
I and II. This responsibility has been delegated to the Administrator 
of the DEA by 28 CFR 0.100. The Administrator in turn, has redelegated 
this function to the Deputy Administrator, pursuant to 28 CFR 0.104.
    On November 7, 2008, a notice of proposed 2009 aggregate production 
quotas for certain controlled substances in schedules I and II was 
published in the Federal Register (73 FR 66256). This notice stipulated 
that the DEA would adjust the quotas in 2009 as provided for in 21 CFR 
part 1303.
    The proposed revised 2009 aggregate production quotas represent 
those quantities of controlled substances in schedules I and II that 
may be produced in the United States in 2009 to provide adequate 
supplies of each substance for: The estimated medical, scientific, 
research and industrial needs of the United States; lawful export 
requirements; and the establishment and maintenance of reserve stocks. 
These quotas do not include imports of controlled substances for use in 
industrial processes.
    The proposed revisions are based on a review of 2008 year-end 
inventories, 2008 disposition data submitted by quota applicants, 
estimates of the medical needs of the United States, product 
development, and other information available to the DEA.
    Therefore, under the authority vested in the Attorney General by 
Section 306 of the CSA (21 U.S.C. 826), and delegated to the 
Administrator of the DEA by 28 CFR 0.100, and redelegated to the Deputy 
Administrator pursuant to 28 CFR 0.104, the Deputy Administrator hereby 
proposes the following revised 2009 aggregate production quotas for the 
following controlled substances, expressed in grams of anhydrous acid 
or base:

------------------------------------------------------------------------
                                      Previously
                                      established      Proposed revised
     Basic class--schedule I         initial  2009        2009 quotas
                                        quotas
------------------------------------------------------------------------
2,5-Dimethoxyamphetamine........                 2 g                 2 g
2,5-Dimethoxy-4-ethylamphetamine                 2 g                 2 g
 (DOET).........................
3-Methylfentanyl................                 2 g                 2 g
3-Methylthiofentanyl............                 2 g                 2 g
3,4-Methylenedioxyamphetamine                   25 g                25 g
 (MDA)..........................
3,4-Methylenedioxy-N-                           10 g                10 g
 ethylamphetamine (MDEA)........
3,4-                                            20 g                20 g
 Methylenedioxymethamphetamine
 (MDMA).........................
3,4,5-Trimethoxyamphetamine.....                 2 g                 2 g
4-Bromo-2,5-dimethoxyamphetamine                 2 g                 2 g
 (DOB)..........................
4-Bromo-2,5-                                     2 g                 2 g
 dimethoxyphenethylamine (2-CB).
4-Methoxyamphetamine............                27 g                27 g
4-Methylaminorex................                 2 g                 2 g
4-Methyl-2,5-                                    2 g                 2 g
 dimethoxyamphetamine (DOM).....
5-Methoxy-3,4-                                   2 g                 2 g
 methylenedioxyamphetamine......
5-Methoxy-N,N-                                   5 g                 5 g
 diisopropyltryptamine..........
Acetyl-alpha-methylfentanyl.....                 2 g                 2 g
Acetyldihydrocodeine............                 2 g                 2 g
Acetylmethadol..................                 2 g                 2 g
Allylprodine....................                 2 g                 2 g
Alphacetylmethadol..............                 2 g                 2 g
Alpha-ethyltryptamine...........                 2 g                 2 g
Alphameprodine..................                 2 g                 2 g
Alphamethadol...................                 2 g                 2 g
Alpha-methylfentanyl............                 2 g                 2 g
Alpha-methylthiofentanyl........                 2 g                 2 g
Aminorex........................                 2 g                 2 g
Benzylmorphine..................                 2 g                 2 g
Betacetylmethadol...............                 2 g                 2 g
Beta-hydroxy-3-methylfentanyl...                 2 g                 2 g
Beta-hydroxyfentanyl............                 2 g                 2 g
Betameprodine...................                 2 g                 2 g
Betamethadol....................                 2 g                 2 g
Betaprodine.....................                 2 g                 2 g
Bufotenine......................                 3 g                 3 g
Cathinone.......................                 3 g                 3 g
Codeine-N-oxide.................               602 g               602 g

[[Page 36513]]

 
Diethyltryptamine...............                 2 g                 2 g
Difenoxin.......................             3,000 g             3,000 g
Dihydromorphine.................         2,549,000 g         2,549,000 g
Dimethyltryptamine..............                 3 g                 3 g
Gamma-hydroxybutyric acid.......         24,200,00 g        24,200,000 g
Heroin..........................                20 g                20 g
Hydromorphinol..................                 2 g                 2 g
Hydroxypethidine................                 2 g                 2 g
Ibogaine........................                 1 g                 1 g
Lysergic acid diethylamide (LSD)                10 g                10 g
Marihuana.......................         4,500,000 g         4,500,000 g
Mescaline.......................                 7 g                 7 g
Methaqualone....................                 5 g                 5 g
Methcathinone...................                 4 g                 4 g
Methyldihydromorphine...........                 2 g                 2 g
Morphine-N-oxide................               605 g               605 g
N-Benzylpiperazine..............                 2 g                 2 g
N,N-Dimethylamphetamine.........                 7 g                 7 g
N-Ethylamphetamine..............                 2 g                 2 g
N-Hydroxy-3,4-                                   2 g                 2 g
 methylenedioxyamphetamine......
Noracymethadol..................                 2 g                 2 g
Norlevorphanol..................                52 g                52 g
Normethadone....................                 2 g                 2 g
Normorphine.....................                16 g                16 g
Para-fluorofentanyl.............                 2 g                 2 g
Phenomorphan....................                 2 g                 2 g
Pholcodine......................                 2 g                 2 g
Psilocybin......................                 7 g                 7 g
Psilocyn........................                 7 g                 7 g
Tetrahydrocannabinols...........           312,500 g           312,500 g
Thiofentanyl....................                 2 g                 2 g
Trimeperidine...................                 2 g                 2 g
------------------------------------------------------------------------


------------------------------------------------------------------------
                                      Previously
                                      established      Proposed revised
    Basic class--schedule II         initial  2009        2009 quotas
                                        quotas
------------------------------------------------------------------------
1-Phenylcyclohexylamine.........                 2 g                 2 g
1-                                               2 g                 2 g
 Piperdinocyclohexanecarbonitril
 e..............................
Alfentanil......................             8,000 g             8,000 g
Alphaprodine....................                 2 g                 2 g
Amobarbital.....................                 3 g                 3 g
Amphetamine (for sale)..........        17,000,000 g        17,000,000 g
Amphetamine (for conversion)....         5,000,000 g         5,000,000 g
Cocaine.........................           247,000 g           247,000 g
Codeine (for sale)..............        39,605,000 g        39,605,000 g
Codeine (for conversion)........        65,000,000 g        65,000,000 g
Dextropropoxyphene..............       106,000,000 g       106,000,000 g
Dihydrocodeine..................         1,200,000 g         1,200,000 g
Diphenoxylate...................           947,000 g           947,000 g
Ecgonine........................            83,000 g            83,000 g
Ethylmorphine...................                 2 g                 2 g
Fentanyl........................         1,428,000 g         1,428,000 g
Glutethimide....................                 2 g                 2 g
Hydrocodone (for sale)..........        55,000,000 g        55,000,000 g
Hydromorphone...................         3,300,000 g         3,300,000 g
Isomethadone....................                 2 g                 2 g
Levo-alphacetylmethadol (LAAM)..                 3 g                 3 g
Levomethorphan..................                 5 g                 5 g
Levorphanol.....................            10,000 g            10,000 g
Lisdexamfetamine................         6,200,000 g         6,200,000 g
Meperidine......................         8,600,000 g         8,600,000 g
Meperidine Intermediate-A.......                 3 g                 3 g
Meperidine Intermediate-B.......                 7 g                 7 g
Meperidine Intermediate-C.......                 3 g                 3 g
Metazocine......................                 1 g                 1 g
Methadone (for sale)............        25,000,000 g        25,000,000 g
Methadone Intermediate..........        26,000,000 g        26,000,000 g
Methamphetamine.................         3,130,000 g         3,130,000 g
------------------------------------------------------------------------

[[Page 36514]]

 
[680,000 grams of levo-desoxyephedrine for use in a non-controlled, non-
 prescription product; 2,405,000 grams for methamphetamine mostly for
 conversion to a schedule III product; and 45,000 grams for
 methamphetamine (for sale)]
------------------------------------------------------------------------
Methylphenidate.................        50,000,000 g        50,000,000 g
Morphine (for sale).............        35,000,000 g        35,000,000 g
Morphine (for conversion).......       100,000,000 g       100,000,000 g
Nabilone........................             9,002 g             9,002 g
Noroxymorphone (for sale).......            10,000 g            10,000 g
Noroxymorphone (for conversion).         9,000,000 g         9,000,000 g
Opium (powder)..................         1,050,000 g           230,000 g
Opium (tincture)................           230,000 g         1,050,000 g
Oripavine.......................        15,000,000 g        15,000,000 g
Oxycodone (for sale)............        77,560,000 g        77,560,000 g
Oxycodone (for conversion)......         3,400,000 g         3,400,000 g
Oxymorphone.....................         2,000,000 g         2,000,000 g
Oxymorphone (for conversion)....        12,000,000 g        12,000,000 g
Pentobarbital...................        28,000,000 g        28,000,000 g
Phenazocine.....................                 1 g                 1 g
Phencyclidine...................                20 g                20 g
Phenmetrazine...................                 2 g                 2 g
Phenylacetone...................                 1 g                 1 g
Racemethorphan..................                 2 g                 2 g
Remifentanil....................               500 g               500 g
Secobarbital....................            67,000 g            67,000 g
Sufentanil......................            10,300 g            10,300 g
Tapentadol \1\..................                 0 g           519,000 g
Thebaine........................       126,000,000 g       126,000,000 g
------------------------------------------------------------------------
\1\ Tapentadol was placed in schedule II of the Controlled Substances
  Act by a final order published by the Drug Enforcement Administration
  on May 21, 2009 (74 FR 23790).

    The Deputy Administrator further proposes that aggregate production 
quotas for all other schedules I and II controlled substances included 
in 21 CFR 1308.11 and 1308.12 remain at zero.
    All interested persons are invited to submit their comments in 
writing or electronically regarding this proposal following the 
procedures in the ADDRESSES section of this document. A person may 
object to or comment on the proposal relating to any of the above-
mentioned substances without filing comments or objections regarding 
the others. If a person believes that one or more of these issues 
warrant a hearing, the individual should so state and summarize the 
reasons for this belief. Persons wishing to request a hearing should 
note that such requests must be written and manually signed; requests 
for a hearing will not be accepted via electronic means.
    In the event that comments or objections to this proposal raise one 
or more issues which the Deputy Administrator finds warrant a hearing, 
the Deputy Administrator shall order a public hearing by notice in the 
Federal Register, summarizing the issues to be heard and setting the 
time for the hearing as per 21 CFR 1303.13(c).

Regulatory Certifications

Regulatory Flexibility Act

    The Deputy Administrator hereby certifies that this action will not 
have a significant economic impact upon small entities whose interests 
must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601-
612. The establishment of aggregate production quotas for schedules I 
and II controlled substances is mandated by law and by international 
treaty obligations. The quotas are necessary to provide for the 
estimated medical, scientific, research and industrial needs of the 
United States, for lawful export requirements, and the establishment 
and maintenance of reserve stocks. While aggregate production quotas 
are of primary importance to large manufacturers, their impact upon 
small entities is neither negative nor beneficial. Accordingly, the 
Deputy Administrator has determined that this action does not require a 
regulatory flexibility analysis.

Executive Order 12866

    The Office of Management and Budget has determined that notices of 
aggregate production quotas are not subject to centralized review under 
Executive Order 12866.

Executive Order 13132

    This action does not preempt or modify any provision of state law; 
nor does it impose enforcement responsibilities on any state; nor does 
it diminish the power of any state to enforce its own laws. 
Accordingly, this action does not have federalism implications 
warranting the application of Executive Order 13132.

Executive Order 12988

    This action meets the applicable standards set forth in Sections 
3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform.

Unfunded Mandates Reform Act of 1995

    This action will not result in the expenditure by state, local, and 
tribal governments, in the aggregate, or by the private sector, of 
$120,000,000 or more (adjusted for inflation) in any one year, and will 
not significantly or uniquely affect small governments. Therefore, no 
actions were deemed necessary under the provisions of the Unfunded 
Mandates Reform Act of 1995.

Congressional Review Act

    This action is not a major rule as defined by Section 804 of the 
Small Business Regulatory Enforcement Fairness Act of 1996 
(Congressional Review Act). This action will not result in an annual 
effect on the economy of $100,000,000 or more; a major increase in 
costs or prices; or significant adverse effects on competition, 
employment,

[[Page 36515]]

investment, productivity, innovation, or on the ability of United 
States-based companies to compete with foreign-based companies in 
domestic and export markets.

    Dated: July 16, 2009.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E9-17536 Filed 7-22-09; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.